May 21, 2024 02:00 AM EDTUpdated 06:22 AM
R&D

GSK says long-act­ing asth­ma treat­ment clears two Phase 3 stud­ies

Lei Lei Wu

News Reporter

GSK an­nounced Tues­day morn­ing that its ex­per­i­men­tal an­ti­body treat­ment re­duced the year­ly rate of asth­ma at­tacks across two key clin­i­cal tri­als for ado­les­cents and adults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times